Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn’s disease

Abstract

AIM:To investigate changes in oxidative stress in Crohn's disease (CD) before and after anti-tumor necrosis factor (TNF)-α treatment. METHODS:A total of 42 patients with active CD, who were scheduled to be treated by anti-TNF-α antibodies, were enrolled. Serum levels of diacron-reactive oxygen metabolites (d-ROM), biological antioxidant potential (BAP), and modified ratio of oxidative stress and antioxidant capacity (m-OA) were measured using the Free Radical Analytical System before and 8 wk after induction of therapy with infliximab or adalimumab. The values for oxidative stress were correlated with disease activity and clinical response as determined by the CD activity index (CDAI) at 8 and 54 wk after the therapy. RESULTS:Prior to treatment, d-ROM showed significant correlations with CDAI (r = 0.42, P < 0.01).There was a significant negative correlation between m-OA and CDAI before and after treatment (r = -0.48 vs r = -0.42, P < 0.01). CDAI and d-ROM had decreased significantly by 8 wk after treatment (CDAI; 223.3 ± 113.2 vs 158.3 ± 73.4, P < 0.01, d-ROM; 373 ± 133 vs 312 ± 101, P < 0.05). However, neither BAP nor m-OA had changed significantly. In patients who had responded to the treatment at 8 wk, d-ROM, BAP, and m-OA levels before treatment did not differ significantly between patients with and without loss of response. CONCLUSION: Anti-TNF-α therapy decreases oxi- Clinical Trials Study

Oxidative Stress Indexes for Diagnosis of Health or Disease in Humans

“…In addition, two modifications to the BAP/dROMs ratio have emerged. First a proposal of Yamamoto et al (2015) called mOA that is an adjustment of the ratio by the constant 7.541 [114]: mOA=BAP/dROMs7.451.…”

“…In both OSI, the oxidative part is the measurement of total peroxides or hydroperoxides, which are the oxidation products of several molecules, such as lipids, proteins, and amino acids; therefore, this is a measure of oxidative damage, what does not happen with the antioxidant capacity. The TAC and BAP have different principles, as well as their measurement units; both determinate the total nonenzymatic antioxidant capacity of biological samples, but although BAP is the most recommended procedures [125], the results of the different studies shown that this parameter almost does not change, making the index show no difference [114, 115, 122], especially when it is used to see the antioxidant potential (BAP/dROMs).…”

Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis

“…A recent study that measured baseline protein levels of several cytokines in colon mucosa also found no differences [13]. Connection between anti-TNF loss of response and ROS response was also suggested in a post-treatment study of expression markers in colon [60]; however, measurements of the actual ROS in baseline serum of the NR and Re patients did not find any difference between the two groups [61]. It is possible that the “potential” differences in inflammation, cytokine and ROS responses between the NR and Re patients become relevant only after the therapy start.…”